Omalizumab in children and adolescents with chronic urticaria: a 16 week real-world study

by admin | Jun 1, 2021

Omalizumab (Xolair®) is a recombinant humanized monoclonal anti-IgE antibody, which binds to free IgE, lowers free IgE levels, and causes FcεRI receptors on basophils and mast cells to be downregu-lated. Omalizumab is the first drug approved as an add-on therapy for...

The chronic urticaria registry: rationale, methods, and initial implementation

by admin | May 31, 2021

Background Chronic urticaria (CU) is a common disease, characterized by the recurrent appearance of wheals, angioedema or both for more than 6 weeks. Its underlying biology is not well understood, and many patients do not obtain sufficient relief from recommended...

The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

by admin | May 31, 2021

Introduction: The COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: To understand how CU patients are affected by the COVID-19 pandemic; how...

Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria

by admin | May 31, 2021

Purpose: Patients with chronic spontaneous urticaria (CSU) have an increased risk for comorbid autoimmune diseases. In this retrospective multicenter study of CSU patients, we evaluated clinical and laboratory features of CSU associated with a higher risk of comorbid...

Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: a systematic review

by admin | May 31, 2021